Advertisement
Advertisement
IMCR
Immunocore Holdings plc - ADR
31.11
USDSponsored
-1.31
-4.03%
Sep 23, 11:52 UTC -4
Open
IMCR Earnings Reports
Positive Surprise Ratio
IMCR beat 13 of 23 last estimates.
57%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$115.43M
/-$0.12
Implied change from Q2 26 (Revenue/ EPS)
-0.43%
/+500.00%
Implied change from Q3 25 (Revenue/ EPS)
+11.32%
/--
Immunocore Holdings plc - ADR earnings per share and revenue
On Aug 06, 2026, IMCR reported earnings of -0.02 USD per share (EPS) for Q2 26, missing the estimate of 0.01 USD, resulting in a -290.48% surprise. Revenue reached 115.93 million, compared to an expected 112.58 million, with a 2.97% difference. The market reacted with a +3.63% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 115.43 million USD, implying an increase of 500.00% EPS, and decrease of -0.43% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Immunocore Holdings plc - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Immunocore Holdings plc - ADR reported EPS of -$0.02, missing estimates by -290.48%, and revenue of $115.93M, 2.97% above expectations.
How did the market react to Immunocore Holdings plc - ADR's Q2 2026 earnings?
The stock price moved up 3.63%, changed from $33.29 before the earnings release to $34.50 the day after.
When is Immunocore Holdings plc - ADR expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Immunocore Holdings plc - ADR's next earnings report?
Based on 12
analysts, Immunocore Holdings plc - ADR is expected to report EPS of -$0.12 and revenue of $115.43M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.